ArticleInternational health2026
A qualitative study on pre-exposure prophylaxis uptake and retention among men who have sex with men and transgender women in Myanmar.
Article in International health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Oral pre-exposure prophylaxis (PrEP) is efficacious in reducing human immunodeficiency virus transmission among people at substantial risk. In Myanmar's PrEP demonstration project among men who have sex with men (MSM) and transgender women (TGW), 39% (n=216) of eligible MSM/TGW initiated daily oral PrEP and 43% (n=93) of them remained on PrEP at 1 y. Here we aimed to understand the barriers and facilitators of PrEP uptake and retention among Myanmar's MSM/TGW and healthcare providers. We conducted three focus group discussions among 29 MSM/TGW (PrEP users and non-users) and in-depth interviews among 18 MSM/TGW and 8 healthcare providers (non-PrEP and PrEP prescribers) from Yangon. Interviews were audio recorded and transcribed in Burmese. Transcripts were analysed using thematic analysis. Among 47 participating MSM/TGW, the median age was 27 y, half identified as TGW (51% [n=24]) and 49% (n=23) were MSM and 53% (n=25) were taking PrEP during the study. Among healthcare providers, the median age was 31 y, seven were male, one was female and half were PrEP providers. In our study, perceived stigma linked with homosexuality, the daily pill burden and community misconceptions of PrEP as antiretroviral therapy were barriers. Providing telemedicine services and incentives and having a supportive network and peers facilitated PrEP uptake and retention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.